Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 9;10(9):e037961.
doi: 10.1136/bmjopen-2020-037961.

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease

Takaomi Kessoku  1   2 , Takashi Kobayashi  1 , Anna Ozaki  1 , Michihiro Iwaki  1 , Yasushi Honda  1   2 , Yuji Ogawa  1 , Kento Imajo  1 , Yusuke Saigusa  3 , Koji Yamamoto  3 , Takeharu Yamanaka  3 , Haruki Usuda  4 , Koichiro Wada  4 , Masato Yoneda  1 , Satoru Saito  1 , Atsushi Nakajima  5
Affiliations

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease

Takaomi Kessoku et al. BMJ Open. .

Abstract

Introduction: Non-alcoholic fatty liver disease (NAFLD) pathogenesis involves abnormal metabolism of cholesterol and hepatic accumulation of toxic free-cholesterol. Elobixibat (EXB) inhibits the ileal bile acid (BA) transporter. EXB and cholestyramine (CTM) facilitate the removal of free cholesterol from the liver by decreasing BA recirculation to the liver, thereby stimulating novel BA synthesis from cholesterol. In this randomised, double-blind, placebo-controlled, parallel-group, phase IIa study, we aim to provide a proof-of-concept assessment by evaluating the efficacy and safety of EXB in combination with CTM in patients with NAFLD.

Methods and analysis: A total of 100 adult patients with NAFLD, diagnosed based on low-density lipoprotein cholesterol (LDL-C) level of >120 mg/dL and liver fat content of ≥8% by MRI-based proton density fat fraction (MRI-PDFF), who meet the inclusion/exclusion criteria will be enrolled. The patients will be randomly assigned to receive the combination therapy of 10 mg EXB and 9 g CTM powder (4 g CTM), 10 mg EXB monotherapy, 9 g CTM powder monotherapy or a placebo treatment (n=25 per group). Blood tests and MRIs will be performed 16 weeks following treatment initiation. The primary study endpoint will be the absolute LDL-C level change at week 16 after treatment initiation. The exploratory endpoint will include absolute changes in the liver fat fraction as measured by MRI-PDFF. This proof-of-concept study will determine whether the combination therapy of EXB and CTM is effective and safe for patients with NAFLD.

Ethics and dissemination: Ethics approval was obtained from the Ethics Committee of Yokohama City University Hospital before participant enrolment. The results of this study will be submitted for publication in international peer-reviewed journals and the key findings will be presented at international scientific conferences.

Trial registration number: NCT04235205.

Keywords: adult gastroenterology; clinical trials; gastroenterology; hepatobiliary disease.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Data will be retained in accordance with the Japanese ethical guidelines for clinical research. Participants will be allocated a unique identification (ID) number at entry. The master list linking participant personal information and ID number will be maintained in a separate locked cabinet and password-protected hard drive. Data will be analysed by ID number only. Records will be retained for 5 years after study completion, and then destroyed by the data center. AN reports grants and research support from Gilead, Mylan EPD, EA Pharma, Kowa, Taisho, Biofermin; is a consulting adviser for Gilead, Boehringer Ingelheim, BMS, Kowa, Astellas, EA Pharma, Mylan EPD. Other authors declare no competing interests.

Figures

Figure 1
Figure 1
Study design. aN=100 enrolled. CTM, cholestyramine; EXB, elobixibat; NAFLD, non-alcoholic fatty liver disease; PBO, placebo; QD, quaque die.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Eguchi Y, Hyogo H, Ono M, et al. . Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012;47:586–95. 10.1007/s00535-012-0533-z - DOI - PubMed
    1. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005;129:375–8. 10.1053/j.gastro.2005.05.041 - DOI - PubMed
    1. Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res 2013;52:175–91. 10.1016/j.plipres.2012.11.002 - DOI - PubMed
    1. Ferslew BC, Xie G, Johnston CK, et al. . Altered bile acid metabolome in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2015;60:3318–28. 10.1007/s10620-015-3776-8 - DOI - PMC - PubMed
    1. Aranha MM, Cortez-Pinto H, Costa A, et al. . Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2008;20:519–25. 10.1097/MEG.0b013e3282f4710a - DOI - PubMed

Publication types

MeSH terms

Associated data